“The Older, the Wiser” in Prostate Cancer Treatment Choices?
Menée sur une cohorte de 3 183 hommes atteints d'un cancer de la prostate non métastatique (durée de suivi : 14 ans), cette étude prospective américaine évalue l'effet de l'âge, des caractéristiques tumorales au diagnostic et de la comorbidité sur la mortalité spécifique et la mortalité associée à d'autres causes
In this issue, Daskivich and colleagues investigated the effect of age, tumor risk, and comorbidity on survival in a large population-based cohort of men older than 60 years with prostate cancer. Their findings suggest that the number of comorbid conditions is effective in predicting mortality across age groups. The editorialists discuss the study and its findings, concluding that consideration of these factors may help to identify certain older men who are unlikely to benefit from aggressive therapy.
Annals of Internal Medicine , éditorial, 2012